Meeting
2019 Genitourinary Cancers Symposium
Toxicity results from a novel phase I/II trial of VMAT radiotherapy to prostate and pelvic nodes plus six cycles of radium-223 in mCSPC metastatic to bone post ADT and docetaxel.
Authors
Joe O'Sullivan
Centre for Cancer Research and Cell Biology, Queen's University, Belfast, United Kingdom
Joe O'Sullivan , Philip Geoffrey Turner , Suneil Jain , Alan R. Hounsell , Darren M. Mitchell , Sandra Biggart , Arthur Grey , Aidan Cole
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer,Prostate Cancer
Sub Track
Prostate Cancer - Advanced Disease
Clinical Trial Registration Number
2014-000273-39
Citation
J Clin Oncol 37, 2019 (suppl 7S; abstr 196)
DOI
10.1200/JCO.2019.37.7_suppl.196
Abstract #
196
Poster Bd #
H17
Abstract Disclosures
Similar Posters
Poster
2018 Genitourinary Cancers Symposium
Patterns of response to androgen deprivation therapy in younger patients with locally advanced or metastatic prostate cancer.
First Author: Matthew Keating
Poster
2024 ASCO Genitourinary Cancers Symposium
Clinical and patient factors associated with treatment intensification for metastatic castration-sensitive prostate cancer.
First Author: Sreevalsa Appukkuttan
Poster
2023 ASCO Annual Meeting
The relationship between a priori defined prognostic risk groups and and overall survival (OS) in men with metastatic hormone sensitive prostate cancer (mHSPC).
First Author: Susan Halabi
Poster
2022 ASCO Genitourinary Cancers Symposium
Progression-free survival (PFS) and overall survival (OS) in patients (pts) with de-novo, high-volume metastatic castration-sensitive prostate cancer (dn-hv-mCSPC) undergoing intensified androgen deprivation therapy (ADT).
First Author: Umang Swami